HC Wainwright Has Positive Forecast for RNTX FY2026 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX – Free Report) – HC Wainwright increased their FY2026 earnings estimates for Rein Therapeutics in a report issued on Wednesday, November 18th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.41) per share for the year, up from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.48) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at ($0.56) EPS and FY2030 earnings at $0.36 EPS.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Wednesday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.00.

Check Out Our Latest Analysis on RNTX

Rein Therapeutics Stock Down 8.9%

Shares of NASDAQ:RNTX opened at $0.34 on Friday. Rein Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.10. The business’s 50 day moving average is $0.66 and its 200 day moving average is $0.98. The stock has a market cap of $29.06 million, a P/E ratio of -0.21 and a beta of 1.47.

Institutional Investors Weigh In On Rein Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC grew its holdings in Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares in the last quarter. Rock Creek Group LLC grew its holdings in shares of Rein Therapeutics by 40.0% during the third quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock worth $141,000 after buying an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc increased its holdings in shares of Rein Therapeutics by 19.9% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock valued at $290,000 after purchasing an additional 60,000 shares during the period. Marshall Wace LLP purchased a new position in Rein Therapeutics during the 3rd quarter worth $127,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Rein Therapeutics in the second quarter valued at about $260,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.

Featured Stories

Earnings History and Estimates for Rein Therapeutics (NASDAQ:RNTX)

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.